8-K/A - ELTP - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K/A

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(D)

OF

THE SECURITIES EXCHANGE ACT OF 1934

November 10, 2025

Date

of Report (Date of earliest event reported)

ELITE

PHARMACEUTICALS INC /NV/

ELITE

PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-15697	22-3542636
(State<br> or other jurisdiction	(Commission	(IRS<br> Employer
of<br> incorporation)	File<br> Number)	Identification<br> No.)

165 Ludlow Avenue, Northvale, New Jersey

07647

(Address of principal executive offices)

(201)

750-2646

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> Stock, par value $0.001 per share	ELTP	OTCQB

Explanatory

Note

This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Elite Pharmaceuticals, Inc. (the “Company”) on November 10, 2025, solely to correct the date of the conference call in Item 7.01.

Item7.01. Regulation FD Disclosure.

On November 10, 2025, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) issued a press release announcing that the company will host a conference call to discuss its financial results for the second quarter of fiscal year 2026 ended September 30, 2025, on Monday, November 17, 2025, at 11:30 AM EST. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

ConferenceCall Information

Date:	November<br> 17, 2025
Time:	11:30<br> AM EST
Dial-in<br> numbers:	1-800-346-7359<br> (domestic)
	1-973-528-0008<br> (international)
Conference<br> number:	98840
Questions:	dianne@elitepharma.com
	General<br> questions by 5:00 PM EST on Thursday, November 13, 2025
	Financial<br> questions by 7:00 PM EST on Friday, November 14, 2025

The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit<br> No.	Description
99.1	Press Release dated November 10, 2025
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:<br> November 12, 2025	ELITE<br> PHARMACEUTICALS, INC.
By:	/s/ Nasrat Hakim
---	---
	Nasrat<br> Hakim, President and CEO

Exhibit99.1

ElitePharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update

andDiscuss Second Quarter 2026 Financial Results on November 17, 2025

Financialsfor Second Quarter of Fiscal Year 2026 Ended September 30, 2025

willbe released on Friday, November 14, 2025

Northvale, NJ – November 10, 2025: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite’s management will host a live conference call on Monday, November 17^th^, at 11:30 AM EST to discuss the company’s financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.

Date:	November<br> 17, 2025
Time:	11:30<br> AM EDT
Dial-in<br> numbers:	1-800-346-7359<br> (domestic)<br><br> 1-973-528-0008 (international)
Conference<br> number:	98840
Questions:	dianne@elitepharma.com<br> <br><br> General questions by 5:00 PM EST on Thursday, November 13, 2025<br><br> Financial questions by 7:00 PM EST on Friday, November 14, 2025
Audio<br> Replay:	https://elite.irpass.com/events_presentations

AboutElite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

For Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations, 518-398-6222

Dianne@elitepharma.com